Abstract
Pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare subtype of non-small cell lung cancer. While first line treatment for stage IV disease with gemcitabine plus either cisplatin (GP) or carboplatin (GC) is more established with encouraging objective response rate, there is no consensual subsequent treatment strategy upon progression. In view of their potent efficacy in the first line setting, re-challenge gemcitabine-platinum is considered a reasonable option, but efficacy data is currently lacking.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
